Maggie Gu

As China General Manager, Maggie is responsible for establishing and operating Immune-Onc’s China entity as well as supporting global drug development and corporate strategic leadership.

Maggie has a wealth of clinical development and organization management experience in the pharmaceutical industry in China, along with deep understanding of oncology. She has successfully led development and registration activities of a series of innovative products in oncology, dermatology, respiratory and other areas in China, including Tuoyi®, Tagrisso®, Lynparza®, Botox®, Avodart®, Hepsera®, Protopic®, etc.

Maggie joins Immune-Onc from Ipsen where, as Vice President and head of R&D Shanghai Innovation Hub, she helped to establish a R&D footprint in China and advance specialty care portfolio strategy smoothly. Before that, she was Vice President of Clinical Development in Shanghai Junshi Biosciences where she successfully led the team to achieve marketing authorization of Tuoyi® (toripalimab) as the first China- developed and approved anti-PD-1 drug. Prior to Junshi, Maggie’s previous roles included Senior Director-Clinical Development in Clinical Operations at AstraZeneca, Head of Clinical Operations and Therapeutic Area Medical Science Director at GlaxoSmithKline, and Medical Affairs Manager at Fujisawa.

Maggie has been actively leading or involved in various committees shaping the China drug innovation and clinical trial environment including the R&D-based Pharmaceutical Association Committee (RDPAC) Clinical Research Working Group, Medical Intelligence Committee of Chinese Society of Clinical Oncology (CSCO), Clinical Research Promotion Committee, among others.

Prior to joining the pharmaceutical industry, Maggie worked in the Pediatric Research Institute, Children’s Hospital affiliated to Shanghai Medical University. Maggie earned her master's degree in pediatric medicine at Shanghai Medical University.